What Is Geron Corporation's Downside Risk? [The Motley Fool]
Geron Corporation (GERN)
Last geron corporation earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
geron.com/investors
Company Research
Source: The Motley Fool
Management's bold moves have been steadily stemming concerns about the company's future. Geron Corporation ( NASDAQ:GERN ) , a clinical-stage cancer company, has grabbed the attention of growth investors due to its enormous upside potential. The short version of the story is that Geron is awaiting a critical continuation decision by partner Johnson & Johnson ( NYSE:JNJ ) in regards to their blood cancer collaboration for the telomerase inhibitor imetelstat. If J&J opts in, Geron will be in line for a milestone payment ranging from $65 million to $135 million, depending on whether the company decides to exercise its co-development and promotion rights going forward. On the other hand, the drug's rights would return in full to Geron if J&J walks away. Image source: Getty Images. As it's extremely tempting to only focus on the upside potential of speculative biotech stocks, I think investors would be wise to do the opposite and seriously weigh Geron's dow
Show less
Read more
Impact Snapshot
Event Time:
GERN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GERN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GERN alerts
High impacting Geron Corporation news events
Weekly update
A roundup of the hottest topics
GERN
News
- Geron to Announce First Quarter 2024 Financial Results on May 2, 2024Business Wire
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Considering The Merits Of A Gamble On Geron Corporation [Seeking Alpha]Seeking Alpha
- Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future [Yahoo! Finance]Yahoo! Finance
- Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.MarketBeat
GERN
Earnings
- 2/28/24 - Beat
GERN
Sec Filings
- 3/27/24 - Form ARS
- 3/27/24 - Form DEFA14A
- 3/27/24 - Form DEF
- GERN's page on the SEC website